home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410n.zip
/
M94A2439.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
37 lines
Document 2439
DOCN M94A2439
TI Associated seroconversion to HIV-HBV.
DT 9412
AU Roberto F; Raiteri R; Sciandra M; Sinicco A; Inst. of Infect. Diseases,
Univ. of Turin, Italy.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):304 (abstract no. PC0146). Unique
Identifier : AIDSLINE ICA10/94370136
AB OBJECTIVE: To assess the associated seroconversion to HIV-HBV (HIV-HBV
SC) among i.v. drug users (IDUs). METHODS: From March 1986 to December
1993, 120 out of 2368 IDUs periodically tested for HIV and HBV markers,
with negative test for HIV within the previous 6 months had
seroconversion to HIV (group A). As controls, 364 IDUs matched by sex,
age and i.v. drug use characteristics, who remained negative to HIV at
the end of the study, were employed (group B). RESULTS: Fourteen of 41
participants negative to HBV markers had HBV infection in group A vs 20
of 144 in group B (OR = 3.2; p = .006). On univariate analysis, HIV-HBV
SC was related to drug debut after 1988 (OR = 6.5; CI = 1.21-34.5; p =
.019), recent debut of drug use (OR = 5.3; CI = 1.2-23.7; p = .021),
high frequency of drug injecting (OR = 8.7; CI = 1.9-39.8, p = .003),
alcohol abuse (OR = 1.33; CI = 0.19-9.1; p = .000), high number of
sexual partners (OR = 3.8; CI = 0.97-14.9; p = .000) and history of STDs
(OR = 4.33; CI = 0.36-52.6; p = .000). On multivariate analysis, only
high frequency of i.v. drug injecting remained independently linked to
HIV-HBV SC (beta = 2.72; OR = 15.2; p = .01). CONCLUSIONS: Counseling
and early vaccinal program to HBV are to be tailored primarily to IDUs
who start injecting and are susceptible to HBV because of the influence
that HIV and HBV may have on each other.
DE Hepatitis B/PREVENTION & CONTROL/TRANSMISSION Hepatitis B
Antibodies/*ANALYSIS Human HIV Infections/TRANSMISSION *HIV
Seropositivity Risk Factors Substance Abuse,
Intravenous/*COMPLICATIONS MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).